| 标题 |
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Georg Lenz; Marek Trněný; John M Burke; Grzegorz S Nowakowski; Christopher P Fox; et al 出版日期:2026 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)